Originally developed in the 1950s as a malaria treatment, hydralazine showed antihypertensive ability and was soon repurposed.[A186841] Hydralazine is a hydrazine derivative vasodilator used alone or as adjunct therapy in the treatment of hypertension and only as adjunct therapy in the treatment of heart failure.[A186820,L8782,L8785] Hydralazine is no longer a first line therapy for these indications since the development of newer antihypertensive medications.[T691] Hydralazine hydrochloride was FDA approved on 15 January 1953.[L8779]
Synonyms
(1Z)-1(2H)-Phthalazinone hydrazone
Hydrazinophthalazine
(2H)-Phthalazinone hydrazone
Phthalazin-1-ylhydrazine
Hydralazine hydrochloride
1-Hydrazinophthalazine
Idralazina
Hydrazone 1(2H)-phthalazinone
Hypophthalin
Hydralazin
6-Hydralazine
Hydralazinum
Hydrallazine
Hydralazine
1-Phthalazinylhydrazine
Hidralazina
Brand Names
PMS-hydralazine
HydrALAZINE hydrochloride
Hydralazine Hydrocloride
HydrALAZINE Hydrochloride
Isosorbide Dinitrate and Hydralazine Hydrochloride
Hydralazine HCl and Hydrochlorothiazide
Hydralazine Hydrochloride Injection, USP
BiDil
Hydralazine
Hydralazine-50 Tab
Apo-hydralazine
Jamp-hydralazine
Apresoline Tablets, 50mg
Nu-hydral Tab 50 mg
hydrALAZINE Hydrochloride
Apresoline Tablets, 25mg
Isosorbide dinitrate and hydralazine hydrochloride
Novo-hylazin Tab 50mg
Apresoline Tablets, 10mg
Hydralazine Hydrochloride Injection
Hydralazine HCl
Apresoline hydrochloride
Nu-hydral Tab 25mg
Ser-AP-ES Tab
Apresoline
Asn-hydralazine
Hydralazine Hydrochloride
Hydralazine-10 Tab 10mg
Mint-hydralazine
Hydralazine-25 Tab
Ser-Ap-Es
Novo-hylazin Tab 25mg
Nu-hydral Tab 10mg
Novo-hylazin Tab 10mg USP
Indication
Hydralazine is indicated alone or adjunct to standard therapy to treat essential hypertension.[L8782] A combination product with isosorbide dinitrate is indicated as an adjunct therapy in the treatment of heart failure.[L8785]
Categories
Antihypertensive Agents
Antihypertensive Agents Indicated for Hypertension
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682